The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Monoallelic TP53-mutated CLL patients show durable response to ibrutinib monotherapy
Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, describes how a recent study found chronic lymphocytic leukemia (CLL) patients responded better to ibrutinib monotherapy if they only had a monoallelic TP53 aberration, compared to those with biallelic. Monoallelic TP53-mutated patients had better progression-free survival compared to biallelic patients. This knowledge has the potential to identify patients who would benefit from single-agent ibrutinib therapy and those who would not. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
